| Literature DB >> 35370471 |
Shuai Zhou1,2, GuangWei Ren2, YuKun Liu3, XiaoMing Liu2, LiHong Zhang2, ShuFeng Xu4, Tao Wang2.
Abstract
Loss of renal function may render hemodialysis patients more susceptible to infectious diseases, which is the second of all-causes mortality in this population. In addition to infection caused by the classic Klebsiella pneumoniae (cKp), however, hemodialysis staffs are now facing new challenge with growing prevalence of the carbapenem-resistant Kp (CR-Kp) and hypervirulent Kp (hvKp) as they are respectively associated with increased drug-resistance and virulence. We therefore chose to share our recent experience in treating severe infections either caused (cKp, CR-Kp, hvKp) or complicated (CR-hvKp) by these strains in hemodialysis patients. Based upon yet beyond published works, we further came up with the detection of intracranial lesion, novel diagnostic approach using unique biomarkers followed by selection of appropriate antibiotics, management of metastasic abscesses and bracing for the most lethal scenario in the order of cKp, CR-Kp, hvKp and CR-hvKp, respectively. Since reports of complicated hvKp infection in hemodialysis patients were rare, we also discussed in details this clinical entity focusing on its epidemiology, mechanism of increased virulence and involvement of the arteriovenous fistula as insidious source of persistent septicemia. By covering the full spectrum of clinically relevant Kp stains specifically from the viewpoint of nephrology, our work had highlighted the importance of infection control in uremic state and vice versa. As such, it may greatly raise the awareness of dialysis staffs against the challenge of evolving Klebsiella pneumoniae infection in hemodialysis patients and expeditiously reach a higher degree of readiness which was proved to be the key determinant of ultimate survival. © The author(s).Entities:
Keywords: antibiotic; arteriovenous fistula; carbapenem-resistant; hypervirulent Klebsiella pneumoniae; maintenance hemodialysis
Mesh:
Substances:
Year: 2022 PMID: 35370471 PMCID: PMC8964319 DOI: 10.7150/ijms.69577
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Figure 1Clinical course and imaging findings in the patient with cKp infection. A: Major therapeutic procedures during the patient's hospital stay. B: The first CT scan after admission showing pulmonary infection and hepatic abscess. C: The second CT scan after the patient was transferred in showing gross normal pulmonary field and drained hepatic abscess. D: Contrast-enhanced MRI showing lesion on the right temporal lobe. E: CT scan prior to discharge. TEC and CSSS: teicoplanin and cefoperazone sodium and sulbactam sodium, respectively.
Figure 2Clinical course and imaging findings in the patient with CR-Kp infection. Part-1 Management of the patient prior to his transferring to our department. A: Major therapeutic procedures during the patient's hospital stay. Red dots and blue cross indicated the patient's heart rate and temperature, respectively. Joint antibiotics use was at the bottom of the panel. B: CT scan 2-week after admission showing pulmonary infection and hepatic abscess. C: CT scan 12-day after the patient was transferred in showing right segmental atelectasis and significantly reduced hepatic abscess. D and E: CT scans immediately after the onset of cerebral hemorrhage and 2-week prior to his discharge, respectively. F: CT scan 10-day shortly before the discharge. Part-2 Management of the patient after his transferring to our department. A (continued): Major therapeutic procedures and joint antibiotics use at the bottom of the panel. G: accessory genes by which the four distinct Kp strains were genetically defined (adapted from Ref. 5 by Martin RM et al., Front Cell Infect Microbiol. 2018) H: comparison of the β-lactamase inhibitors and spectrum of inhibition. (adapted from Ref. 25 by Bush K et al., Nat Rev Microbiol. 2019) mNGS: metagenomics next generation sequencing. CRRT: continuous renal replacement therapy. XR-AB and XR-PA: multiple drug resistance Acinetobacter baumannii and Pseudomonas aeruginosa, respectively. HD: hemodialysis. TEC: teicoplanin. IPM: imipenem. FLICZ: fluconazol. DBO: diazabicyclooctanone analogue. ESBL: extended-spectrum β-lactamase. MBL: metallo-β-lactamase.
Figure 3Clinical, imaging and morphologic characterization in the patient with hvKp infection. A: Clinical course of the patient's hospital stay. B1: Chest CT scan at admission. B2-4: CT scan on hospital day 9 showing abscess of the lung, liver and spleen (arrow), respectively. C1 and C2: Tumoral dilation and purulent exudation of the arteriovenous fistula, prior to and after the fistulectomy, respectively; C3 and C4: scene reconstruction of the fingertip abscesses.
Figure 4Clinical course and imaging findings in the patient with positive isolation of CR-hvKp. A: Major therapeutic procedures during the patient's hospital stay. B: Bedside plain X-ray showing cardiomegaly and pulmonary edema. C: Echocardiography showing left ventricular thrombus. D and E: CT scan at the day of transfer showing pulmonary patchy ground-glass opacity, pleural effusion and gross normal liver, respectively. IABP: intra-aortic balloon counterpulsation. F: mNGS results showing the detection of multiple drug resistance genes including the KPC and characteristic genes for hvKp.
Clinical features and laboratory results during the patient's hospital stay
| Admission | Pre-fistulectomy | Post-fistulectomy | Finger Abscesses | post-Abscess incision | |
|---|---|---|---|---|---|
| Hospital Stay (day) | 1 | 14 | 17 | 36 | 44 |
| T (ºC) | 38.3 | 38.3 | 37.0 | 36.3 | 36.4 |
| SaO2 (%) | 88 | 97-99 | 97-99 | 97-99 | 97-99 |
| BP (mmHg) | 132/80 | 135/72 | 132/77 | 138/85 | 150/95 |
| WBC (×109) | 15.0 | 14.8 | 13.6 | 6.1 | 6.1 |
| Neutrophil (%) | 96.3 | 84.6 | 87.7 | 75.1 | 64.0 |
| Lymphocyte (%) | 2.8 | 6.5 | 6.6 | 13.4 | 16.3 |
| Hemoglubin (g/L) | 80 | 56* | 97 | 68 | 83 |
| Platelet (×109) | 56 | 89 | 263 | 184 | 366 |
| NLR | 34.4 | 13.0 | 13.3 | 5.6 | 3.9 |
| CRP (mg/L) | 350.5 | 117.4 | 97.0 | 8.3 | 7.5 |
| PCT (ng/mL) | >50.0 | 13.0 | 3.1 | 3.1 | 0.5 |
| D-dimer (ng/mL) | 1005 | 4830 | 5102 | 688 | 404 |
| Albumin (g/L) | 33.4 | 21.5 | 24.3 | 29.4 | 32.1 |
| GOT (U/L) | 87.3 | 13.0 | 18.3 | 14.5 | 19.1 |
| GPT (U/L) | 69.2 | 11.8 | 12.1 | 12.4 | 13.8 |
| Scr (µmol/L) | 778.8 | 795.8 | 649.4 | 600.8 | 404.1 |
| FBS (mmol/L) | 26.4 | 9.1 | 8.0 | 7.5 | 7.7 |
| Ferritin (ng/mL) | 992.7 | 1007.2 | 721.6 | 671.0 | 853.2 |
BP: blood pressure. WBC: white blood cell. NLR: neutrophil-to-lymphocyte ratio. CRP: C-reaction protein. PCT: precalcitoninnin;
GOT and GPT: glutamate oxaloacetate transaminase and glutamate pyruvate transaminase, respecctively. Scr: serum creatinine;
FBS: fasting blood sugar. *Blood transfusion initiated.